OMER
Omeros Corporation
There isn't enough reported data to score OMER yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
OMER Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
OMER's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
OMER PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 1x | $1.76 | -90% |
| Fair | 5.3x | $9.22 | -49% |
| Forward | 5.5x | $17.99 | — |
| Expensive | 10x | $17.82 | -1% |
| Current | 10x | $17.99 | — |
Historical ranges are pointers, not guarantees.
OMER's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over OMER in the historical PE scenario, which offers more potential upside but is not a forecast.
OMER Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OMER to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
OMER Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.25 | +88% |
| Q2 2026 | $1.73 | +$3.84 |
| Q1 2026 | $1.15 | +$3.80 |
| Q4 2025 | -$0.05 | +$2.65 |
| Q3 2025 | -$2.02 | +$0.28 |
| Q2 2025 | -$2.11 | +$0.23 |
| Q1 2025 | -$2.65 | -$0.69 |
| Q4 2024 | -$2.70 | -$0.83 |
| Q3 2024 | -$2.30 | -797% |
OMER has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
OMER Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2021 | $30M | +15% |
| Q2 2021 | $28.8M | +113% |
| Q1 2021 | $21.1M | -11% |
| Q4 2020 | $10.6M | -68% |
| Q3 2020 | $26.1M | -13% |
OSCR has the stronger quarterly revenue trend. Revenue is up 35% for OMER versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 0.3% | N/A |
| Q1 2026 | -176% | N/A |
| Q3 2021 | -61% | +37 points |
| Q2 2021 | -83% | +121 points |
| Q1 2021 | -145% | -45 points |
| Q4 2020 | -318% | -247 points |
| Q3 2020 | -97% | -60 points |
| Q2 2020 | -205% | N/A |
OMER's operating margin was 0.3% last quarter, up 146 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over OMER on profitability, with a higher operating margin.
OMER Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.1M | +$26.1M |
| Q1 2026 | -$14.5M | +$21.4M |
| Q4 2025 | -$39.8M | -$10.8M |
| Q3 2025 | -$18.5M | +$13.6M |
| Q2 2025 | -$22M | +$24.1M |
| Q1 2025 | -$35.9M | +$6M |
| Q4 2024 | -$29M | +$5.9M |
| Q3 2024 | -$32.1M | +$621K |
OMER has burned cash in almost every quarter: −$69M over the past year, against −$119M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over OMER on cash generation, producing positive trailing cash flow while its opponent burns cash.
OMER Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -491K shares |
| 1 year | +53% | +31M shares |
| 3 years | +43% | +26.8M shares |
| 5 years | +44% | +27.3M shares |
| Available history | +82% | +40.3M shares |
OMER has 90M diluted shares, up 53% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $5.7M |
| Q1 2026 | $4.2M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
OMER spent $10M buying back its own shares over the past year, after none the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over OMER on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OMER Net Leverage
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
OMER Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.2 | Neutral |
| Stochastic | 62.7 | Neutral |
OMER's weekly RSI is 57 (neutral) and its Stochastic is 63 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
OMER PE vs Healthcare Sector
| Metric | OMER | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 85 | 29 | 56 pts above |
OMER has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OMER Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.1 | 0.5% below |
| 20 week MA | $16.0 | 13% above |
| 50 week MA | $13.4 | 34% above |
| 100 week MA | $9.89 | 82% above |
| 200 week MA | $7.06 | 155% above |
OMER's trend is up, with a small recent dip: it's below only its 8-week average, and 155% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over OMER on trend strength, trading above more of its moving averages.
OMER Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.0 | $14.9 | -0.7% |
| 2021 | $14.9 | $7.64 | -49% |
| 2022 | $7.64 | $2.54 | -67% |
| 2023 | $2.54 | $3.27 | +29% |
| 2024 | $3.27 | $11.7 | +257% |
| 2025 | $11.7 | $15.7 | +35% |
| 2026 YTD | $15.7 | $18.0 | +15% |
OMER's yearly returns have swung widely, from +257% in 2024 to −67% in 2022. It's up 15% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over OMER on returns for 2026, with the stronger performance.